abstract |
The present invention relates to compounds of formula (I) The compounds of the present invention have been found to be very likely NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD): Formula I Where R 1 , R 2 , R 3 , R ', Ar, o, n and m are as defined in the specification. |